Alex Blyth, a serial biotech entrepreneur and inventor working across oncology and longevity science, has come to view immune competence as a key influence on healthspan, disease susceptibility, and the broader trajectory of aging. He says, "The body's capacity to distinguish accurately between healthy tissue and potential threats plays an important role in how well people age." Biological age, in this framing, may reflect a downstream expression of a more fundamental variable: the quality of immune judgment.
This perspective has emerged from more than two decades immersed in life sciences innovation. Blyth is the founder and former CEO of LIfT BioSciences, a company developing neutrophil-based immunotherapies designed to address solid tumors by rejuvenating innate immune responses. Over the course of his career, he has contributed to the development and commercialization of healthcare assets and has held strategic roles in healthcare consulting and biotech venture building.
